Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)

Trial Profile

Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms C_ASCENT
  • Most Recent Events

    • 08 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top